Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.

Campbell MR, Amin D, Moasser MM.

Clin Cancer Res. 2010 Mar 1;16(5):1373-83. doi: 10.1158/1078-0432.CCR-09-1218. Epub 2010 Feb 23.

2.

Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.

Littlefield P, Liu L, Mysore V, Shan Y, Shaw DE, Jura N.

Sci Signal. 2014 Dec 2;7(354):ra114. doi: 10.1126/scisignal.2005786.

3.

The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.

Amin DN, Campbell MR, Moasser MM.

Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9. Review.

4.

HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.

Kol A, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Lamberts LE, Bensch F, de Vries EG, Schröder CP.

Pharmacol Ther. 2014 Jul;143(1):1-11. doi: 10.1016/j.pharmthera.2014.01.005. Epub 2014 Feb 7. Review.

PMID:
24513440
5.

An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.

Xia W, Petricoin EF 3rd, Zhao S, Liu L, Osada T, Cheng Q, Wulfkuhle JD, Gwin WR, Yang X, Gallagher RI, Bacus S, Lyerly HK, Spector NL.

Breast Cancer Res. 2013;15(5):R85.

6.

The role of HER3 in gastric cancer.

Wang L, Yuan H, Li Y, Han Y.

Biomed Pharmacother. 2014 Jul;68(6):809-12. doi: 10.1016/j.biopha.2014.08.011. Epub 2014 Aug 20. Review.

PMID:
25194439
7.

The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.

Zaczek A, Brandt B, Bielawski KP.

Histol Histopathol. 2005 Jul;20(3):1005-15. doi: 10.14670/HH-20.1005. Review.

PMID:
15944951
8.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
9.

ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.

Choi BK, Fan X, Deng H, Zhang N, An Z.

Cancer Med. 2012 Aug;1(1):28-38. doi: 10.1002/cam4.10. Epub 2012 Jul 15.

10.

Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.

Poovassery JS, Kang JC, Kim D, Ober RJ, Ward ES.

Int J Cancer. 2015 Jul 15;137(2):267-77. doi: 10.1002/ijc.29378. Epub 2014 Dec 19.

11.

Targeting HER proteins in cancer therapy and the role of the non-target HER3.

Hsieh AC, Moasser MM.

Br J Cancer. 2007 Aug 20;97(4):453-7. Epub 2007 Jul 31. Review.

12.

Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.

Wu Y, Zhang Y, Wang M, Li Q, Qu Z, Shi V, Kraft P, Kim S, Gao Y, Pak J, Youngster S, Horak ID, Greenberger LM.

Mol Cancer Ther. 2013 Apr;12(4):427-37. doi: 10.1158/1535-7163.MCT-12-0838. Epub 2013 Feb 8.

13.

The upgraded role of HER3 and HER4 receptors in breast cancer.

Koutras AK, Fountzilas G, Kalogeras KT, Starakis I, Iconomou G, Kalofonos HP.

Crit Rev Oncol Hematol. 2010 May;74(2):73-8. doi: 10.1016/j.critrevonc.2009.04.011. Epub 2009 May 30. Review.

PMID:
19481955
14.

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.

Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser MM.

Nature. 2007 Jan 25;445(7126):437-41. Epub 2007 Jan 7.

15.

HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells.

Kong A, Calleja V, Leboucher P, Harris A, Parker PJ, Larijani B.

PLoS One. 2008 Aug 6;3(8):e2881. doi: 10.1371/journal.pone.0002881.

17.

Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.

Servidei T, Riccardi A, Mozzetti S, Ferlini C, Riccardi R.

Int J Cancer. 2008 Dec 15;123(12):2939-49. doi: 10.1002/ijc.23902.

19.

Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals.

Kadioglu O, Cao J, Saeed ME, Greten HJ, Efferth T.

Target Oncol. 2015 Sep;10(3):337-53. doi: 10.1007/s11523-014-0339-4. Epub 2014 Nov 21. Review.

PMID:
25410594
20.

HER2/HER3 signaling regulates NK cell-mediated cytotoxicity via MHC class I chain-related molecule A and B expression in human breast cancer cell lines.

Okita R, Mougiakakos D, Ando T, Mao Y, Sarhan D, Wennerberg E, Seliger B, Lundqvist A, Mimura K, Kiessling R.

J Immunol. 2012 Mar 1;188(5):2136-45. doi: 10.4049/jimmunol.1102237. Epub 2012 Feb 1.

Supplemental Content

Support Center